Skip to content

A Co-created Self-care and Informal Support Intervention Study Among Women With GDM in Vietnam

Living Together With Chronic Disease: Informal Support for Diabetes Management in Vietnam (VALID) - Gestational Diabetes in Vietnam - Phase II

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05744856
Acronym
VALID-II
Enrollment
435
Registered
2023-02-27
Start date
2023-01-16
Completion date
2025-04-20
Last updated
2026-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GDM

Keywords

GDM, Co-creation, Self-care, Vietnam, Low-and-middle-income countries, Informal support, Intervention

Brief summary

Gestational Diabetes Mellitus (GDM) is significant public health problem in Vietnam, which is potentially treatable if managed properly by the pregnant women once diagnosed. However, systematic screening for GDM is rarely undertaken in Vietnam, and little is known about how health providers, pregnant women, and their families in today's Vietnam handle the condition. Vietnamese women often depend on their extended family for daily life management and access to social and financial resources, hence, an intervention that focuses on informal support and GDM self-care may increase adherence the standard guidelines among pregnant women with GDM in Vietnam and increase neonatal and maternal health outcomes.

Detailed description

Background: Across the globe, diabetes mellitus is attaining epidemic proportions, with low- and middle-income countries confronting particularly high burdens. VALID II focuses on gestational diabetes mellitus (GDM), a transitory form of diabetes that presents during pregnancy. Objectives: To: i) Determine prevalence and risk factors for GDM among pregnant women in Vietnam's Thai Binh province, ii) Measure the associations between GDM and pregnancy complications and outcomes, iii) Understand how pregnant women with GDM and their informal support persons perceive and handle the condition, iv) Co-create, implement, and assess the feasibility of a intervention aiming to enhance the self-care capacities of pregnant women with GDM. Study setting: Thai Binh, Vietnam Study design: Intervention study Study population: 2,000 pregnant women attending antenatal care. Methodology: The study will be performed as a pilot parallel 2-arm non-randomized intervention study with a delayed-start for the intervention group. 1000 women will be invited into the study at their first antenatal care visit (gestational week 12) and complete a questionnaire (inclusion questionnaire). All women will be offered a 2-hour oral glucose tolerance test (OGTT) in gestational week 24-28 and complete second questionnaire (OGTT questionnaire) exploring living conditions, lifestyle, risk factors, selfcare, perceived social support, perceived wellbeing, and sign of depression. An estimated 200 women (\ 20%) will screen positive for GDM by the OGTT according to the World Health Organization (WHO) 2013 diagnostic criteria and receive standard GDM care. These 200 women will serve as the study's control group (study phase I). Among the 200 women who screen positive in phase I, ethnographic interviews will be formed in a subgroup of 20 women. The information from the 20 ethnographic interviews and the 200 questionnaire interviews will help inform a co-created "self-care and informal support" intervention. Subsequently, another 1000 women will be invited into the study at their first antenatal care visit and be offered a 2-hour oral glucose tolerance test (OGTT) in gestational week 24-28 (study phase II). An estimated 200 women (\ 20%) will screen positive for GDM, and these women will receive the co-created intervention and serve as the study's intervention group. Additionally, all women (both intervention and control group) will be interviewed in gestational week 32-36 and 8-12 weeks postpartum. Further, information about HbA1c, maternal BMI, gestational weight gain, mode of delivery, neonatal weight as well as obstetric and neonatal complications will be obtained from measurements and the delivery records. The primary endpoint will be large for gestational age. Secondary neonatal endpoints will be macrosomia, preterm birth, stillborn/neonatal death and neonatal hypoglycemia. Secondary maternal outcomes will be HbA1c, hypertensive disorders, gestational weight gain, caesarean section, women's GDM self-care, perceived social support, perceived wellbeing, signs of depression, breastfeeding rates, quality of life, and empowerment. The outcome of this intervention pilot study will determine whether the intervention can be feasibly delivered within the context of a full-scale randomized controlled trial (RCT). Thus, the pilot study will not be powered to detect statistical differences in key clinical outcomes, but the sample sizes have been chosen to highlight problems and confirm the potential to detect differences. Women may be included in the study all the way up to gestational age 28 depending on when they attend their first antenatal care appointment and receive the OGTT. Further, the point in time of the different questionnaire interviews may vary according to the needs of the pregnant women and when she delivers.

Interventions

BEHAVIORALSelf-care with informal support

The detailed content of the "self-care with informal support intervention" will be developed at participatory co-creation workshops involving pregnant women with GDM, their informal support persons, and health care staff. It is expected that intervention will include educational pamphlets regarding GDM and digital GDM education through videos and text messages. Further, digital coaching will be conducted and networking among intervention participants via the Vietnamese messaging app Zalo. In addition, each woman will be invited to include one informal support person in the intervention activities. GDM education will concern coaching on diet and exercise during pregnancy and after delivery and coaching on breastfeeding and infant/child nutrition.

Sponsors

Thai Binh University of Medicine and Pharmacy
Lead SponsorOTHER
University of Copenhagen
CollaboratorOTHER
University of Southern Denmark
CollaboratorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Masking description

Due to the overt nature of the intervention, it is not possible to blind the participants, healthcare providers nor the investigators.

Intervention model description

The study is parallel 2-arm non-randomized intervention study with a delayed-start for the intervention group. The study population will be recruited in two phases. Over a period of 4 months (phase I) 1000 pregnant women will be screened for GDM among which 200 will be diagnosed with GDM and receive standard GDM care according to national guidelines in Vietnam (control group). During phase I, the "self-care + informal support intervention" will be co-created with local health care staff and a sub-group of the control group. Four months after the recruitment for phase I has finished, recruitment for phase II will start. Over a period of 4 months, another 1000 pregnant will be screened for GDM among which 200 will be diagnosed with GDM. These 200 women will be invited to receive the "self-care + informal support" intervention (intervention group). This pilot study is designed to inform a power calculation and logistics of a future full-scale randomized controlled trial.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Pregnancy \< 28 weeks * Singleton and multiple pregnancies * Residing in Thai Binh province * Speaks and reads Vietnamese * Agree to participate voluntarily (informed consent)

Exclusion criteria

* Pre-gestational diabetes (type I or type II) * Severe chronic disease Women with GDM in a prior pregnancy are eligible for inclusion into the study.

Design outcomes

Primary

MeasureTime frameDescription
The Acceptability of the Self-care InterventionStudy month 3 to 10 /Gestational age 24 to 12 weeks post-partumAcceptability will be measured in a combined quantitative and qualitative study. It will be measured quantitatively via 5-point likert scales among the intervention group \[Range: 1-5; Minimum score: 1; Maximum score: 5; Higher score indicates high acceptability\]. It will be assessed qualitatively among a sub-group of the intervention group through a ethnographic study.
Large for Gestational Age (LGA)Delivery (up to study month 7 after enrolment/Gestational age 40)Number of Participants who delivered newborns with birth weight above or equal to the 90th percentile according to gender and gestational age based on the INTERGROWTH-21st birthweight chart
The Feasibility of the Self-care Intervention [Recruitment]Recruitment (study month 0)Number of Participants eligible for the study who accepted to be included in the intervention arm.
The Feasibility of the Self-care Intervention [Retention]Recruitment to post-partum evaluation (study month 0-10)Number of Participants included in the self-care intervention group who completed the study (delivery data and post-partum interview).

Secondary

MeasureTime frameDescription
MacrosomiaDelivery (study month 7/Gestational age 40)Number of newborns with birth weight above 4000g
Macrosomia (Vietnam)Delivery (study month 7/Gestational age 40)Number of newborns with birth weight above 3500g
Live-bornDelivery (study month 7/Gestational age 40)Newborns that are live-born (Yes/no)
Small for Gestational Age (SGA)Delivery (study month 7/Gestational age 40)Number of newborns below the 10th percentile for birth weight according to gestational age
Apgar ScoreDelivery (study month 7/Gestational age 40)The Apgar score of newborns measured 1 and 5 minutes after delivery (score: 0-10)
Neonatal HypoglycemiaDelivery (study month 7/Gestational age 40)Measurement of blood glucose (mmol/l) in newborns
Maternal Gestational Weight GainStudy month 0 and 6/Gestational age 12 and 36Change in delta weight (kilogram) among participants between gestational age 36 minus first measured/pre-gestational weight
HbA1cStudy month 3 and 7/Gestational age 24 and 40 (delivery)Change in delta score among participants between gestational age 24 and 40 (delivery)
Breast Feeding PracticesStudy month 10 (12 weeks post-partum)Participants' breast feeding practices measured through ad hoc developed questions
Post-partum DepressionStudy month 3 and 10/Gestational age 24 and 12 weeks postpartumChange in delta score among participants measured through the Edinburgh postpartum depression scale (EPDS) \[10 items on 4-point scale ranging from 0-3\]
Perceived Social SupportStudy month 3,6 and 10/Gestational age 24, 36 and 12 weeks postpartumChange in delta score among participants measured through the Multidimensional Scale of Perceived Social Support scale (MSPSS) \[11 item 7-point scale ranging from 1-7\]
Well-beingStudy month 0, 3, 6 and 10/Gestational age 12, 24, 36 and 12 weeks postpartumChange in delta scores measured through WHO 5 Wellbeing index \[5 items on 6-point scale ranging from 0-5\]
Self-care AgencyStudy month 3 and 6/Gestational age 24 and 36Difference in score between intervention and comparator group measured through the Self-care Agency Scale-Revised (ASAS-R) \[15 items on 5-point scale ranging from 1-5\]
Mode of DeliveryDelivery (study month 7/Gestational age 40)Number of participants with spontaneous vaginal delivery, assisted vaginal delivery, planned c-section or emergency c-section
Self-care of GDMStudy month 6/Gestational age 36Difference in score between intervention and comparator group measured through the Summary of Diabetes Self- Care Activities (SDSCA) \[10 items on 8-point scale ranging 0-7\]
Pre-term Birth Below Gestational Age 37+0Delivery (study month 7/Gestational age 40)Number of participants with spontaneous preterm birth or medical induced preterm birth
Gestational AgeDelivery (study month 7/Gestational age 40)The gestational age of newborns at delivery
Birth WeightDelivery (study month 7/Gestational age 40)Birth weight of newborns measured in grams

Countries

Vietnam

Contacts

PRINCIPAL_INVESTIGATORThanh Duc Nugyen, MD

Thain Binh Medical University

Baseline characteristics

Characteristic
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
427 Participants
Age, Continuous30.6 years
STANDARD_DEVIATION 5.4
Prepregnancy BMI21.4 kg/m2
STANDARD_DEVIATION 2.8
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
201 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
0 Participants
Region of Enrollment
Vietnam
427 participants
Sex: Female, Male
Female
226 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 2230 / 198
other
Total, other adverse events
0 / 2230 / 198
serious
Total, serious adverse events
0 / 2230 / 198

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 18, 2026